These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 22218118

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Losartan in diabetic nephropathy.
    Perico N, Ruggenenti P, Remuzzi G.
    Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):473-83. PubMed ID: 15225108
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial.
    Navarro JF, Mora C, Muros M, García J.
    J Am Soc Nephrol; 2005 Jul; 16(7):2119-26. PubMed ID: 15917336
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Importance of baseline distribution of proteinuria in renal outcomes trials: lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study.
    Zhang Z, Shahinfar S, Keane WF, Ramjit D, Dickson TZ, Gleim GW, Mogensen CE, de Zeeuw D, Brenner BM, Snapinn SM.
    J Am Soc Nephrol; 2005 Jun; 16(6):1775-80. PubMed ID: 15872078
    [Abstract] [Full Text] [Related]

  • 9. Aldosterone synthase (CYP11B2)-344T/C polymorphism and renoprotective response to losartan treatment in diabetic nephropathy.
    Schjoedt KJ, Lajer M, Andersen S, Tarnow L, Rossing P, Parving HH.
    Scand J Clin Lab Invest; 2006 Jun; 66(3):173-80. PubMed ID: 16714246
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Recent advances in management of type 2 diabetes and nephropathy: lessons from the RENAAL study.
    Keane WF, Lyle PA, Reduction of Endpoints in NIDDM with the Angiotensin II Receptor Antagonist Losartan study.
    Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S22-5. PubMed ID: 12612946
    [Abstract] [Full Text] [Related]

  • 12. Use of losartan in reducing microalbuminuria in normotensive patients with type-2 diabetes mellitus.
    Agha A, Bashir K, Anwar E.
    Nepal Med Coll J; 2007 Jun; 9(2):79-83. PubMed ID: 17899953
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function.
    van den Meiracker AH, Baggen RG, Pauli S, Lindemans A, Vulto AG, Poldermans D, Boomsma F.
    J Hypertens; 2006 Nov; 24(11):2285-92. PubMed ID: 17053552
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Risk and prevention of diabetic nephropathy].
    Ravera M, Re M, Deferrari G.
    G Ital Nefrol; 2007 Nov; 24 Suppl 38():13-9. PubMed ID: 17922442
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.